Biosyent Inc
XTSX:RX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Biosyent Inc
Net Income (Common)
Biosyent Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biosyent Inc
XTSX:RX
|
Net Income (Common)
CA$9m
|
CAGR 3-Years
18%
|
CAGR 5-Years
19%
|
CAGR 10-Years
9%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Net Income (Common)
$157m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Canopy Growth Corp
TSX:WEED
|
Net Income (Common)
-CA$326.6m
|
CAGR 3-Years
53%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Net Income (Common)
-$9.4m
|
CAGR 3-Years
62%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Net Income (Common)
-$168.1m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
-112%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Net Income (Common)
-CA$5.4m
|
CAGR 3-Years
44%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Biosyent Inc
Glance View
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. BioSyent, through its wholly owned subsidiaries BioSyent Pharma Inc. (BioSyent Pharma) and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary of BioSyent, operates in the non-chemical insecticide business. BioSyent products include Combogesic, Aguettant System, Cathejell, Cysview, FeraMAX 150, FeraMAX Powder, Proktis-M, RepaGyn, and TIBELLA. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Aguettant System are used for a variety of injectable medications in hospitals and the acute care setting. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. RepaGyn for the healing of the vaginal mucosa and the treatment of vaginal dryness.
See Also
What is Biosyent Inc's Net Income (Common)?
Net Income (Common)
9m
CAD
Based on the financial report for Dec 31, 2025, Biosyent Inc's Net Income (Common) amounts to 9m CAD.
What is Biosyent Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
9%
Over the last year, the Net Income (Common) growth was 24%. The average annual Net Income (Common) growth rates for Biosyent Inc have been 18% over the past three years , 19% over the past five years , and 9% over the past ten years .
